Topic: undruggable targets
Vividion, which is looking to boost the number of proteins small molecules can target, will advance three programs and expand its early-stage work.
Anima Biotech has signed a deal with Eli Lilly potentially worth more than $1 billion in biobucks as the pair seek to work on the biotech’s translation inhibitors.
The four-year alliance tasks Vividion with discovering drugs that interact with the ubiquitin proteasome system cells used to break proteins apart.
Relay Therapeutics has bumped up its cash with a strong second funding round as it eyes clinical work on its next-gen cancer drug development.
Orum Therapeutics has raised a small series A to help push on with its work on a monoclonal antibody designed to treat undruggable cytosolic targets.
GSK and Warp Drive Bio are combining their drug discovery expertise in a bid to find small-molecule drugs to treat intractable disease targets.
Astellas Pharma has struck a drug discovery deal worth up to $100 million per target with X-Chem.